FFTYCapForce IBD 50 ETF
Tracks the performance of the IBD 50 Index.
By Capital-FORCE ETF · Launched 2015
Annual Cost
0.80%
#4,522 of 6,040 · expensive
Fund Size
$74M
#3,359 of 6,040 · mid-size
Return (1Y)
-3.4%
Track Record
11 years
#1,277 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$8,947-10.5%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Index tracking
Factor
Momentum
Index tracked
IBD 50 Index
Holdings
By weightConcentration
Top 10 holdings = 51.6% of fundmoderately concentrated
Mount Vernon Liquid Assets Portfolio, LLC
19.2%
Mirum Pharmaceuticals Inc
4.1%
Micron Technology Inc
3.9%
AnaptysBio Inc
3.7%
Comfort Systems USA Inc
3.6%
FTAI Aviation Ltd
3.5%
IAMGOLD Corp
3.5%
PACS Group Inc
3.4%
Rocket Lab Corp
3.3%
Celestica Inc
3.3%
Asset allocation
Stocks
99.5%
Cash
1.4%
By sector
Healthcare
39.6%
Technology
17.8%
Basic Materials
15.6%
Financial Services
14.4%
Consumer Cyclical
7.0%
Industrials
5.1%
Communication
0.5%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
36.2%High
Year-on-year price swings
Max drawdown
-59.5%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.49Below average
Sortino (3Y)
0.66Moderate downside risk
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Tracks the performance of the IBD 50 Index.
- Strategy
- Invests at least 80% of net assets in U.S. common stocks that comprise the IBD 50 Index, which identifies the top 50 growth stocks. The Fund uses an indexing investment approach to replicate the Index's performance, with significant exposure to the information technology sector.
- Inception date
- April 8, 2015
- Fund family
- Capital-FORCE ETF
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save FFTY to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18